[go: up one dir, main page]

CA2158173A1 - Method of treating addictive behaviors - Google Patents

Method of treating addictive behaviors

Info

Publication number
CA2158173A1
CA2158173A1 CA002158173A CA2158173A CA2158173A1 CA 2158173 A1 CA2158173 A1 CA 2158173A1 CA 002158173 A CA002158173 A CA 002158173A CA 2158173 A CA2158173 A CA 2158173A CA 2158173 A1 CA2158173 A1 CA 2158173A1
Authority
CA
Canada
Prior art keywords
agonist
addictive behaviors
patient
treating addictive
addictive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002158173A
Other languages
French (fr)
Other versions
CA2158173C (en
Inventor
Pietr Hitzig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2158173A1 publication Critical patent/CA2158173A1/en
Application granted granted Critical
Publication of CA2158173C publication Critical patent/CA2158173C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Treatment of addictive behavior, depression or manic depressive behavior, excluding obesity, is described in which an effective amount of at least one serotonin agonist and at least one dopamine agonist is administered to a patient. The combination of the serotonin agonist and the dopamine agonist are present in an amount effective to treat the patient's addictive behaviar. Pharmaceutical compositions are also disclosed.
CA002158173A 1993-03-17 1994-03-17 Method of treating addictive behaviors Expired - Fee Related CA2158173C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3483493A 1993-03-17 1993-03-17
US08/034,834 1993-03-17
PCT/US1994/002875 WO1994021244A1 (en) 1993-03-17 1994-03-17 Method of treating addictive behaviors

Publications (2)

Publication Number Publication Date
CA2158173A1 true CA2158173A1 (en) 1994-09-29
CA2158173C CA2158173C (en) 2001-12-04

Family

ID=21878899

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002158173A Expired - Fee Related CA2158173C (en) 1993-03-17 1994-03-17 Method of treating addictive behaviors

Country Status (4)

Country Link
EP (1) EP0710106A4 (en)
AU (1) AU6410394A (en)
CA (1) CA2158173C (en)
WO (1) WO1994021244A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4467396A (en) 1994-12-12 1996-07-10 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
US6413961B1 (en) 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
FR2760190B1 (en) * 1997-02-28 1999-04-09 Adir PHARMACEUTICAL COMPOSITION FOR THE PROGRAMMED RELEASE OF DEXFENFLURAMINE
ES2239196T3 (en) 2002-12-02 2005-09-16 Schwarz Pharma Ag IONTOPHORETIC SUPPLY OF ROTIGOTINE FOR THE TREATMENT OF PARKINSON'S DISEASE.
DE10334188B4 (en) 2003-07-26 2007-07-05 Schwarz Pharma Ag Use of rotigotine to treat depression
WO2009091605A2 (en) * 2008-01-17 2009-07-23 Health Innovations, Llc Taste titration therapies
KR102385359B1 (en) 2010-11-08 2022-04-11 오메로스 코포레이션 Treatment of addiction and impulse-control disorders using pde7 inhibitors
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255439A (en) * 1979-07-13 1981-03-10 Irving Cooper Means and method for aiding individuals to stop smoking

Also Published As

Publication number Publication date
AU6410394A (en) 1994-10-11
EP0710106A4 (en) 1999-07-21
EP0710106A1 (en) 1996-05-08
WO1994021244A1 (en) 1994-09-29
CA2158173C (en) 2001-12-04

Similar Documents

Publication Publication Date Title
CA2289717A1 (en) Novel therapy for constipation
KR950002785A (en) Parathyroid hormone and raloxyphene to increase bone mass
CA2317044A1 (en) Medicament for neurodegenerative diseases
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
WO1994027589A3 (en) Antidepressant dosage form
CA2154103A1 (en) Treatment of Mucous Membrane Disease, Trauma or Condition and for the Relief of Pain
MX9704030A (en) 2-heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof.
PL303937A1 (en) Application of an antiestrogen compound and pharmaceutical agent
WO1994008551A3 (en) Pharmaceutical compositions and methods for treating cold symptoms
AU2711295A (en) Combination treatment for inhibiting bone loss
HU9603042D0 (en) Use of certain methanebisphosphonic acid derivatives to prevent or for treatment of prosthesis loosening and prosthesis migration
CA2150185A1 (en) Pharmaceutical composition for the treatment of stoma-peripheral inflammation
CA2157142A1 (en) Treatment of diseases caused by sebaceous gland disorders
GB9305718D0 (en) Medicaments
HK1025250A1 (en) Use of zinc hyaluronate against peptic ulcer
AU5170499A (en) Use of ginkgo biloba extracts for preparing a medicine for treating amyotrophic lateral sclerosis
CA2158173A1 (en) Method of treating addictive behaviors
CA2283255A1 (en) Use of r-nsaid's for the prevention of alzheimer's disease
CA2150183A1 (en) Pharmaceutical composition for the treatment of hemorrhoidal diseases
CA2137595A1 (en) Treating hormone-dependent conditions
BR9814945A (en) Use of phanquinone for the treatment of alzheimer's disease, pharmaceutical composition and kit
EP0744176A3 (en) Methods for inhibiting bone loss
RU94040886A (en) Use of melatonine derivatives for sleep disturbance treatment, pharmaceutical composition
MX9707642A (en) Pharmaceutical agents for the treatment of alzheimer's disease.
RU94041028A (en) Application of melatonin derivatives for treating desynchronization disorders, pharmaceutical composition

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed